Active Biotech Q2 2025: On the Eve of a Laquinimod Deal - Redeye
Redeye comments on Active Biotech's second quarter report. The protocol for the myelofibrosis study is being updated. The biodistribution study of laquinimod finished with excellent results. The company is looking for a partner as the next step.
ANNONS
Redeye comments on Active Biotech's second quarter report. The protocol for the myelofibrosis study is being updated. The biodistribution study of laquinimod finished with excellent results. The company is looking for a partner as the next step.
